Miriam Poirier

Dr. Miriam Poirier


Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2004 in Nature Reviews Cancer
Verified
Journal Article
Closed access
MPMiriam Poirier
Miriam Poirier

1 March 2000 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
MPMiriam Poirier
Miriam Poirier
RSRegina M. Santella
Regina M. Santella
AWAinsley Weston
Ainsley Weston
Damage to DNA induced by carcinogenic chemicals reflects exposure and is directly related to tumor formation, whereas modification of protein provides relatively precise dosimetry for stable adducts of proteins with a known half-life. Sophisticated methods for the detection and quantitation of DNA and protein adducts have been developed during the last ~25 years. For DNA adducts the most widely used methods include electrochemical detection, mass spectrometry, fluorescence and phosphorescence spectroscopy, immunoassays and immunohistochemistry and 32P-post-labeling. Detection limits for quantitative assays are typically in the range of 1 adduct in 107 or 109 nucleotides. However, accelerator mass spectrometry, which is highly sophisticated but less accessible, has a detection limit of ~1 adduct in 1012 nucleotides. Methods for the determination of protein adducts include immunoassay and a variety of elegant high-resolution mass spectrometry approaches. The detection limit of ~0.1 fmol for protein adducts, is based primarily on method specificity and the availability of large quantities of sample material. Using these highly sensitive methods a major achievement has been the biomonitoring of chemically exposed human populations. Validation of macromolecular adduct formation in humans has been predicated on studies in animal models. Adduct formation in humans appears to be indicative of molecular dosimetry and suggestive of increased human cancer risk. However, despite the large body of literature documenting DNA and protein adduct molecular dosimetry for many carcinogen exposures, the relationship between adduct formation and human cancer risk has been defined for only a few carcinogens. Thus, elucidation of this association remains a compelling challenge. For the future, integration of DNA and protein adduct measurements together with documentation of correlative and subsequent events, and host susceptibility factors, within the context of valid molecular epidemiologic study designs, will further our understanding of human disease mechanisms.

1 June 2003 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
MPMiriam Poirier
Miriam Poirier
RDRao L. Divi
Rao L. Divi
LALena Al-Harthi
Lena Al-Harthi
OOOfelia A. Olivero
Ofelia A. Olivero
VNVi Nguyen
Vi Nguyen
WBWilliam A. Blattner
William A. Blattner
Although children born to HIV-infected (HIV+) women receiving antiretroviral therapy during pregnancy show virtually no adverse clinical effects at birth, the antiretroviral nucleoside analog drugs are known to damage nuclear and mitochondrial DNA. In this study, biomarkers of mitochondrial toxicity and genotoxicity have been examined in a well-characterized sample set consisting of infants born to HIV-uninfected (HIV-) mothers (n = 30), and HIV- infants (n = 20) born to HIV-infected (HIV+) mothers who received either no antiretroviral therapy (n = 10) or zidovudine (3′-azido-3′-deoxythymidine [AZT]) during pregnancy (n = 10). DNA from cord blood leukocytes and peripheral blood leukocytes taken at 1 and 2 years of age was examined for loss of mitochondrial DNA (mtDNA) and telomere integrity. Telomere length, a measure of nuclear DNA damage, was the same in all infants at birth and at age 1 year. The quantity of mtDNA was assessed relative to nuclear DNA using a polymerase chain reaction-based chemiluminescence detection (PCR-CID) method that determined mitochondrial D Loop gene copies relative to nuclear 18S RNA gene copies by comparison with a standard curve. MtDNA quantity was expressed as a ratio of gene copy numbers. In infants of uninfected mothers (AZT-/HIV-) at the three time points, the ratios were 442 to 515, whereas in infants of untreated AZT-/HIV+ mothers the ratios were 261 to 297, and in infants of AZT-treated (AZT+/HIV+) mothers the ratios were 146 to 203. At all three time points, differences between the AZT-/HIV-group and the two HIV+ groups were statistically significant (p < .05), and differences between the AZT-/HIV+ and AZT+/HIV+ groups were also statistically significant (p < .05), demonstrating that AZT exposure causes a persistent depletion of mtDNA. The study shows that children of HIV+ mothers are at risk for mitochondrial damage that is further increased in infants of mothers receiving AZT during pregnancy.

MPM. Margaret Pratt
M. Margaret Pratt
KJKaarthik John
Kaarthik John
AMAllan B. MacLean
Allan B. MacLean
SASenait Afework
Senait Afework
DPDavid Phillips
David Phillips
MPMiriam Poirier
Miriam Poirier
Polycyclic aromatic hydrocarbons (PAHs) are combustion products of organic materials, mixtures of which contain multiple known and probable human carcinogens. PAHs occur in indoor and outdoor air, as well as in char-broiled meats and fish. Human exposure to PAHs occurs by inhalation, ingestion and topical absorption, and subsequently formed metabolites are either rendered hydrophilic and excreted, or bioactivated and bound to cellular macromolecules. The formation of PAH-DNA adducts (DNA binding products), considered a necessary step in PAH-initiated carcinogenesis, has been widely studied in experimental models and has been documented in human tissues. This review describes immunohistochemistry (IHC) studies, which reveal localization of PAH-DNA adducts in human tissues, and semi-quantify PAH-DNA adduct levels using the Automated Cellular Imaging System (ACIS). These studies have shown that PAH-DNA adducts concentrate in: basal and supra-basal epithelium of the esophagus, cervix and vulva; glandular epithelium of the prostate; and cytotrophoblast cells and syncitiotrophoblast knots of the placenta. The IHC photomicrographs reveal the ubiquitous nature of PAH-DNA adduct formation in human tissues as well as PAH-DNA adduct accumulation in specific, vulnerable, cell types. This semi-quantative method for PAH-DNA adduct measurement could potentially see widespread use in molecular epidemiology studies.

27 June 2016 in Environmental and Molecular Mutagenesis
Verified
Journal Article
Closed access
PDF file
MPMiriam Poirier
Miriam Poirier

1 December 2002 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
RDRao L. Divi
Rao L. Divi
FBFrederick A. Beland
Frederick A. Beland
PFPeter P. Fu
Peter P. Fu
LTLinda S. Von Tungeln
Linda S. Von Tungeln
BSBernadette Schoket
Bernadette Schoket
MPMiriam Poirier
Miriam Poirier
A chemiluminescence immunoassay (CIA) utilizing antiserum elicited against DNA modified with (±)-7β, 8α-dihydroxy-9α,10α-epoxy-7,8,9,10-tetrahydrobenzo[ a ]- pyrene (BPDE) has been developed and validated to study the formation of polycyclic aromatic hydrocarbon (PAH)–DNA adducts in human tissues. Advantages include a low limit of detection for 10b-(deoxyguanosin- N2 -yl)-7β,8α,9α-trihydroxy-7,8,9,10-tetrahydrobenzo[ a ]pyrene (BPdG, ~1.5 adducts/10 9 nucleotides using 20 μg DNA) and a high signal-to-noise ratio (≥100). The CIA BPDE–DNA standard curve gave 50% inhibition at 0.60 ± 0.08 fmol BPdG (mean ± SE, n = 30), which was a 10-fold increase in sensitivity compared with the dissociation-enhanced lanthanide fluoroimmunoassay (DELFIA). Calf thymus DNA modified with [1,3- 3 H]BPDE was assayed by radiolabeling, 32 P-postlabeling, DELFIA and CIA, and all assays gave similar values. Liver DNAs from mice exposed to 0.5 and 1.0 mg [7,8- 3 H]benzo[ a ]pyrene (BP) were assayed by the same four assays and a dose–response was obtained with all assays. The BPDE–DNA CIA was further validated in MCL-5 cells exposed to 4 μM BP for 24 h, where nuclear and mitochondrial DNA adduct levels were associated with an increase in DNA tail length measured by the Comet assay. Human peripheral blood cell (buffy coat) DNA samples ( n = 43) obtained from 25 individuals who were either colorectal adenocarcinoma patients or controls were assayed by BPDE–DNA CIA. Three samples (7%) were non-detectable, and the remaining 40 samples had values between 0.71 and 2.21 PAH–DNA adducts/10 8 nucleotides. The intra-assay coefficient of variation (CV), for four wells on the same microtiter plate, was 1.85%. Sufficient DNA for two assays, on separate plates, was available for 38 of the 43 samples, and the PAH–DNA adduct values obtained were highly correlated ( r2 = 0.95). Coded duplicate DNA samples from 15 individuals were assayed four times gave an inter-assay CV of 13.8%.